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ABSTRACT Dendritic cells (DCs) are a new cell type ini-
tially identified in mouse Iymphoid organs. Recently, DCs have
been purified from mouse spleen. This paper demonstrates a
functional role of DCs: they are potent stimulators of the pri-
mary mixed leukocyte reaction (MLR). As few as 300-1000 DCs
doubled the proliferative activity of 5 X 106 allogeneic responder
spleen cells, while 0.3-1.0 X 10A DCs induced a maximal stim-
ulation of 30- to 80-fold. Between these extremes, the log of the
MLR response increased linearly with the log of DC numbers.
This dose-response assay was then used to compare the potency
of purified DCs with that of other heterogeneous lymphoid
populations, many of which gave dose-response curves with
similar slopes. The potency of purified DCs as MLR stimulators
was 100-300 times greater than that of unfractionated spleen
cells. When spleen cells were fractionated by simple physical
techniques, MLR-stimulating capacity in the subpopulations
correlated closely with DC numbers. Removal of splenic B or
T lymphocytes, by anti-immunoglobulin or anti-brain serum plus
complement, did not reduce MLR-stimulating capacity. Finally,
several populations, enriched in mononuclear phagocytes but
lacking in DCs, stimulated weakly if at all. We conclude that
DCs are a potent stimulating cell and are at least 100 times more
effective than other major cell subclasses-i.e., B and T lym-
phocytes and macrophages.
Lymphoid dendritic cells (DCs) are a novel population of cells
identified initially on the basis of distinctive cytologic criteria
(1-4). DCs occur in low frequency, accounting for 1% or less
of nucleated cells in peripheral lymphoid organs. They are
readily identified in mouse spleen suspensions, where 80% or
more adhere and spread on glass surfaces (1). DCs are derived
from bone marrow precursors and increase in numbers during
the first few weeks of life (3). They lack most of the differen-
tiation markers of other lymphoid cell types, especially mo-
nonuclear phagocytes and lymphocytes (2). However, recently
we have documented that DCs express both H-2 and Ta al-
loantigens to the same extent as other reactive spleen cells.* We
have also been able to purify splenic DCs, to maintain them in
vitro for several days, and to show that they remain distinctive
in appearance and surface markers.* In this paper, we dem-
onstrate that small numbers of purified DCs reliably induce a
vigorous proliferative response in allogeneic T cells, the hall-
mark of a primary mixed leukocyte reaction (10 MLR). We
then show that the efficacy of various lymphoid organs and
subpopulations in stimulating an MLR appears to depend in
large part on their content of DCs.
MATERIALS AND METHODS
Mice. DBA/2, C57BL/6, CD2F, (BALB/c X DBA/2), and
B6D2F1 (C57BL/6 X DBA/2) mice were obtained from the
Trudeau Institute, Saranac Lake, NY; Flow Laboratories,
Dublin, VA; and The Jackson Laboratory, Bar Harbor, ME.
Mice 6 weeks to 6 months in age, of both sexes, were used.
Antisera. Rabbit anti-mouse brain serum, an anti-T cell re-
agent, was obtained from Accurate Scientific, Hicksville, NY.
This serum: killed 20-30% of spleen cells in the presence of
guinea pig complement (Cordis Laboratories, Miami, FL);
totally abolished the mitogen response to concanavalin A
without altering lipopolysaccharide responses; and killed 85% of
cells proliferating in MLRs, without killing lipopolysacchar-
ide-induced lymphoblasts, both obtained as previously de-
scribed (5). Rabbit anti-mouse K serum was prepared as de-
scribed (6). This serum: killed 50-60% of total spleen cells; re-
moved more than 80% of surface immunoglobulin-bearing cells
(stained by indirect immunofluorescence); abolished more than
80% of the total lipopolysaccharide response; and selectively
immunoprecipitated surface immunoglobulin from radioio-
dinated lymphocytes (W. van Voorhis, personal communica-
tion). An anti H-2b serum was obtained from the Research
Resources Branch, National Institutes of Health. This serum
(labeled D-2) was directed to private specificity 2, of the D end
of the H-2b haplotype. In the presence of complement, D-2
killed 100% of H-2b cells and no H-2d cells.
Lymphoid Cells. Spleen, mesenteric lymph node, and thy-
mus were teased apart and further disrupted on a stainless steel
sieve. Resident peritoneal cells were aspirated from the ab-
dominal cavity, bone marrow cells were flushed from femurs,
and peripheral blood leukocytes were isolated on Ficoll/
Hypaque (Pharmacia, Piscataway, NJ). Cells yields were 6-15
X 107 per spleen, 1-3 X 107 per node, 10-15 X 107 per thymus,
0.5 X 107 per femur, 3-6 X 106 per peritoneal cavity, and 5 X
106 per ml of blood.
Adherent Cells. Samples (0.05-0.15 ml) of lymphoid cells
at 0.2-2.0 X 107/ml were applied in 1% mouse serum/RPMI
1640 culture medium (Grand Island Biologicals, Grand Island,
NY) to 15-mm circular glass coverslips for 1-2 hr at 37°.
Nonadherent cells were dislodged with pasteur pipettes. The
coverslips with adherent cells were then transferred to the wells
in which MLRs were induced. To enumerate and identify
glass-adherent cells, 2-5 X 105 cells were spun into 13-mm
circular coverslips as described (5), and allowed to adhere as
above. Cytocentrifugation produced a uniform distribution of
adherent cells that could be fixed in 1.25% buffered glutaral-
dehyde and examined by phase contrast microscopy.
The adherent spleen population we studied consisted pri-
marily of DCs and macrophages, which could be identified by
cytologic and other criteria (1, 2, *). DCs flatten and extend cell
processes in several directions when adherent to glass. The
nucleus is large and irregular in shape, has a refractile ap-
pearance due to a peripheral rim of heterochromatin, and has
small nucleoli. DCs contain many spherical, phase-dense
Abbreviations: MLR, mixed leukocyte reaction; MHC, major histo-
compatibility complex; DC, dendritic cells; sRBC, sheep erythro-
cytes.
* Steinman, R. M., Kaplan, G., Witmer, M. D. & Cohn, Z. A., J. Exp.
Med., in press.
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granules that are mitochondria, but these cells lack the many
pinocytic vesicles, lysosomes, and surface ruffles characteristic
of macrophages. Splenic macrophages in our preparations are
usually small, ruffled cells that are best identified by the ability
to interiorize sheep erythrocytes opsonized with hyperimmune
antiserum to sheep erythrocytes. These cells develop into much
larger and more actively phagocytic macrophages after 2-3
days of tissue culture. Adherent peritoneal cells consist almost
entirely of macrophages, and DCs are extremely rare (less than
0.1%). An exception occurred with a shipment of B6D2F1 mice
in which 1-5% of the adherent peritoneal cells were DCs (see
Results).
Some DCs in spleen and peritoneal cavity do not adhere to
glass, but will attach and spread in a typical fashion on coverslips
coated with poly(L-lysine) (Sigma Chemical, St. Louis, MO; 25
igg/ml of phosphate-buffered saline for 20 min at room tem-
perature).
Purification of Dendritic Cells. The criteria for monitoring
the purification of DCs are described in detail elsewhere.* The
purification protocol itself involves four steps. A low-density
subpopulation of spleen was obtained by floatation on dense
bovine plasma albumin (Armour Pharmaceuticals, Phoenix,
AZ) columns, density = 1.080 g/cm3, and then a glass-adherent,
low-density fraction was prepared (2). Most DCs floated on the
bovine plasma albumin columns, and some 80% adhered to
glass. The main, if not only, contaminating cells at this stage
were immature macrophages. The third step was to culture the
cells overnight in RPMI 1640 medium supplemented with
penicillin and 50 ,uM 2-mercaptoethanol and serum-either
2.5% heat-inactivated mouse serum or 5% fetal calf serum.
During this period, most of the original adherent population
eluted from, or could easily be dislodged from, the glass surface,
yielding a 90% trypan-blue-negative cell suspension. To remove
macrophages from the eluted cells, rosettes were formed with
heavily opsonized sheep erythrocytes (sRBC). A 5% (vol/
vol) suspension of sRBC was opsonized with an equal volume
of a 1:60 dilution of hyperimmune, rabbit anti-sRBC; a 1:40
dilution under these conditions produced hemagglutination.
The opsonized sRBC were mixed with white cells at a ratio of
30:1, spun into a pellet, and allowed to rosette at 40C, and then
the rosettes were removed by centrifugation on dense bovine
plasma albumin, 1.088 g/cm3. The floating population consisted
of at least 95% DCs, while the pelleting cells contained the
rosetted macrophages and 10-20% nonrosetted DCs. To iden-
tify DCs by cytologic criteria, it was necessary to spin the cells
onto poly(L-lysine)-coated coverslips. Following attachment
and glutaraldehyde fixation, the DCs exhibited irregular shapes,
refractile and often contorted nuclei lacking large nucleoli, and
phase-dense spherical granules that were mitochondria. Pino-
cytic vesicles, abundant lysosomes, and surface ruffling were
absent. As described elsewhere,* the purified DCs were totally
insensitive to treatment with anti-Ig and anti-T cell sera plus
complement, did not rosette sRBC opsonized with antibody and
complement and were all killed by specific anti-Ia or anti-H-2
sera plus complement.
Mixed Leukocyte Reaction (MLR). Cultures were set up in
16-mm diameter, flat-bottomed tissue culture wells (Rochester
Scientific, Rochester, NY) in 1 mL of culture medium, with 1%
heat-inactivated mouse serum and 50,uM 2-mercaptoethanol
as supplements. All cultures contained 4-5 X 106 responder cells
and variable numbers of stimulator cells (see Results). All
stimulators were treated with mitomycin C (Sigma Chemicals),
25 Ag/ml, for 30 min at 37'C. Stimulation was performed
across both allogeneic and semiallogeneic (F1) barriers, using
the mouse strains listed above.
Prior to assay, duplicate cultures were harvested with a
pasteur pipette and spun at 200 X g for 10 min, and the cell
C1050)
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FIG. 1. Kinetics of the proliferative response (P3Hlthymidine
uptake/culture following a 2-hr pulse of 1.8 ,uCi/mi) of 5 X 106 DBA/2
spleen cells with various sources of mitomycin-treated C57BL/6
stimulator cells: 0, 105 purified DCs; A, adherent cells from 3 X 106
low-density spleen cells containing about 105 DCs and "contami-
nated" with 105 immature macrophages; 0, 3 X 106 unfractionated
spleen cells; X, 7 X 106 adherent resident peritoneal cells, which are
more than 90% macrophages and have rare DCs; *, no stimulator
cells.
pellet was resuspended in 2 ml of fresh culture medium; 0.2 ml
of the cell suspension was added in triplicate to Microtest wells
(Rochester Scientific) followed by 0.05 ml of [3H]thymidine
(Schwarz/Mann, Orangeburg, NY; specific activity, 6.0 Ci!
mmol, final concentration 1.8 ,uCi/mi). The cells were cultured
an additional 2 hr and then harvested on a multisample har-
vester. Incorporated [3H]thymiidine was measured with Aquasol
(New England Nuclear, Boston, MA) as scintillant and a liquid
scintillation counter operating at 42% efficiency. All data are
given as means of the microtest assays. Standard deviations were
generally less than 10%i and always less than 20% of the
mean.
RESULTS
DCs Stimulate an MLR. The first evidence that DCs could
stimulate an MLR came from studies of adherent low-density
spleen cells. Coverslips, containing a mixture of 105 DCs and 105
macrophages induced a large and prolonged proliferative re-
sponse in allogeneic spleen cells (Fig. 1). The response peaked
at day 4, and stimulation ratios of 30- to 75-fold over the pro-
liferative activity in unstimulated cells were obtained. The
stimulation ratios were always greater than the ratio induced
by 3 x 106 unfractionated spleen cells (Fig. 1), a typical optimal
dose for the mouse MLR.
To determine if adherent macrophages or DCs were stimu-
lating the MLR, we first examined macrophage-rich popula-
tions from other lymphoid organs. Adherent peripheral blood
and bone marrow leukocytes, which contain mononuclear
phagocytes in varying stages of development (7), were first
tested but did not stimulate (data not shown). Adherent peni-
toneal cells, which generally consist of more than 90% mac-
rophages and rare DCs, gave little or no stimulation of thymi-
dine uptake (Fig. 1, Table 1). Significant stimulation was noted
in one shipment of B6D2F1 mice. However, these mice were
unusual in that adherent peritoneal preparations contained DCs
in numbers comparable to the number present in adherent
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Table 1. MLR-stimulating capacity of subpopulations of peritoneal and spleen cells
Response ([3H]thymidine uptake - background, cpm/culture) after stimulation with
Cells Peritoneal cells, Adherent peritoneal cells, Peritoneal Low-density spleen
(X 10-6) to prepare DBA/2 B6D2F1 cells, DBA/2 cells, B6D2Fj
stimulating Adherent Nonadherent Group 1 Group 2 Group 3 Adherent Adherent
subpopulation* (1) (2) (3) (4) (5) (6) (7)
1.0 8210 76,225 19,625 125,640 37,125 7050 116,150
0.3 7600 49,915 7,080 69,250 11,045 7125 64,500
0.1 1265 20,075 5,520 24,750 2,265 4490 17,850
DCs (X 10-4)t <0.1 0.30 <0.1 2.8 0.15 <0.1 3.1
Macrophages (X 10-4)$ 35 5 30 35 35 40 3
Several experiments in which 5 X 106 C57BL/6 responder spleen cells were stimulated with mitomycin-treated DBA/2 or B6D2F1 (DBA/2
X C57BL/6) cells. The stimulations in columns 1 and 2 were simultaneous, as were those in columns 4, 6, and 7. In all cases, the background
(unstimulated C57BL/6 cells) ranged from 4800 to 5100 cpm per culture.
* Dose used to prepare the stimulating cell population. About 35-40% of peritoneal cells adhere to glass vs. 8% for low-density spleen cells.
t Number of DCs enumerated by phase-contrast microscopy in the stimulating cell inoculum at the 1 X 106 dose.
Number of macrophages enumerated by phase-contrast microscopy and phagocytosis of opsonized sRBC in the stimulating cell inoculum
at the 1 X 106 dose.
low-density spleen cells (Table 1, columns 4 and 7). Taken to-
gether, the data in Table 1 indicate that MLR stimulation could
not be correlated with the numbers of macrophages in the
stimulating preparation.
We then purified DCs from adherent low-density spleen
cells. DCs (105) stimulated an MLR identically to an equivalent
number of adherent low-density DCs (Fig. 1). Similar stimu-
lations were obtained with 105 purified DCs that had been
maintained in culture for a total of 4 days. Also, mitomycin-
treated DCs induced little (less than 2-fold boost in thymidine
uptake) or no change in the proliferative activity of syngeneic
spleen cells.
Proliferating Cells in the DC-Induced MLR. Cells labeled
with [3H]thymidine at day 4 of a 10 MLR induced by 105 pu-
rified DCs had the cytologic features of lymphoblasts in auto-
radiograms of cell smears. These pulse-labeled cells-i.e., cells
in S phase of the proliferative cycle-accounted for 20-50% of
the 2.5-4.0 X 106 viable recovered cells. If the cultures were
treated with antisera plus guinea pig complement prior to
measurement of [3H]thymidine uptake, more than 85 and 95%
of the proliferating cells, respectively, could be shown to carry
the brain antigen(s) characteristic of T cells, and the H-2 anti-
gens of the responder strain. We conclude that small numbers
of purified lymphoid DCs induce a typical 10 MLR in allo-
reactive mouse spleen cells.
Potency of DCs in Inducing an MLR. Detailed dose-re-
sponse curves were necessary to compare the potency of various
cell populations to stimulate an MLR. We first looked at various
doses of purified splenic DCs vs. whole or unfractionated spleen,
using constant numbers of responder spleen cells (Fig. 2). As
few as 0.3-1 X 103 purified DCs induced detectable prolifer-
ative activity-i.e., a stimulation ratio of 2-after 4 days of
culture with 5 X 106 responder cells. The corresponding
threshold dose for whole spleen was 0.3-3 X 105. With in-
creasing doses of stimulators, the log of the proliferative re-
sponse increased linearly with the log of the stimulating cell
dose. The slopes for both purified DCs and unfractionated
spleen were similar in all experiments assayed at day 4, indi-
cating that the stimulating unit in both purified DOs and un-
fractionated spleen worked with similar efficacy (Fig. 2).
However, the number of such stimulatory units, or potency, was
very different. That is, if one determined the number of cells
required for a given level of [3H]thymidine uptake on the linear
portion of the dose-response curve, 1/100th to 1/300th as many
purified DCs were needed in comparison to whole spleen. This
observation has been made in nine different experiments using
either purified DCs or adherent low-density spleen cells. The
maximum response induced by DCs was much greater than
that induced by whole spleen, usually 2- to 4 fold. This response
was obtained with 0.3-1 X 105 DCs vs. 1-3 X 106 unfraction-
ated spleen cells. The ability of unfractionated stimulator spleen
cells to induce an MLR was not enhanced by the addition of
adherent responder low-density spleen cells containing 1 X 105
DCs (data not shown).
A remarkable feature of these dose-response data is that DCs
comprise about 1/200th of normal nucleated spleen cells.
Therefore the bulk of the stimulatory capacity in spleen could
be ascribed to the presence of small numbers of DCs. Or, al-
ternatively, non-DCs in spleen must be extremely weak MLR
stimulators. The remainder of this paper looks at the efficacy
of other lymphoid subpopulations and lymphoid organs to in-
duce an MLR, using the dose-response assay described above
(Fig. 2).
Ability of Additional Mouse Lymphoid Subpopulations
to Induce an MLR. We first manipulated the frequency of DCs
in various spleen cell subpopulations by simple physical tech-
niques. Spleen cells were separated by floatation on dense bo-
vine plasma albumin columns. The low-density fraction, which
contained 15% of the total cells and most of the DCs, was 6 times
more potent than unfractionated spleen in inducing an MLR,
-s 3x105 -
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FIG. 2. Potency of purified DCs (A) vs. unfractionated spleen
(0) in inducing an MLR. Responses (cpm of [3Hjthymidine uptake
- background/culture) were measured at various doses of stimulator
cells, after 4 days of culture. Background was 5410 cpm.
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Table 2. MLR-stimulating capacity of spleen subpopulations
Total % of DCs/
cells spleen nucleated Potency,
Cell fraction X 10-7 cells cells, % cells X 10-4
Unfractionated spleen 40 100 0.5 20
Low-density 6 15 3.0 3
High-density 33 83 0.1 72
Adherent low-density 0.6 1.5 44 4
Nonadherent low-
density 4 10 1.1 11
The composition of the various spleen cell fractions used in the
experiment in Fig. 3 is given. DCs were enumerated by cytologic cri-
teria under phase-contrast microscopy. The potency of the various
cell fractions is given as the number of cells needed to give a 2-fold
boost in thymidine uptake. For adherent and nonadherent low-den-
sity cells, this value is the number of low-density cells used to prepare
these fractions. For example, the actual number of adherent cells that
induced a 2-fold boost in thymidine uptake was 4 X 103 vs. 4 X 104.
whereas the high-density fraction was substantially depleted
(Table 2 and Fig. 3). Low- and high-density cells contained
similar numbers of B and T cells as measured by cytotoxicity
assays (2). The glass-adherent portion of the low-density frac-
tion, which contained 10% of the low-density cells and 80% of
the DCs, exhibited 3 times the stimulating capacity of the
nonadherent cells (Table 2 and Fig. 3). Neither adherent nor
nonadherent low-density cells initially contain many mature
macrophages (2). However, after 2-3 days of culture, large
numbers of typical macrophages arise from the nonadherent
fraction. *
To further examine the contribution of T or B lymphocytes
as MLR stimulators, we removed these cells by treatment with
anti-brain or anti-Ig serum and complement; these antisera kill
most T and B cells, respectively. The nonlysed cells were used
as stimulators, but at proportionately lower numbers than
controls treated with complement alone, or neither antibody
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FIG. 3. Several subpopulations of B6D2Fj spleen cells were ob-
tained and used at different doses to stimulate 5 X 106 C57BL/6 re-
sponder spleen cells for 4 days in vitro. Spleen cells (,&) were first
separated into low- (O) and high- (-) density fractions on dense bo-
vine plasma albumin columns. Then various numbers of low-density
cells were separated into glass-adherent (x) and nonadherent (-&)
fractions. The cell dose that is plotted is the dose used to prepare the
adherent and nonadherent cells, and not the absolute number of
stimulator cells used. The yields of total cells and DCs in these frac-
tions are presented in Table 2.
Table 3. MLR-stimulating capacity after killing of B or T cells
Response (cpm [3H]thymidine uptake -
background/culture)
using spleen cells treated with
Stimulating Rabbit Rabbit
cell dose Culture C anti-mouse anti-mouse
X 10-6 medium only brain + C Ig + C
3 121,250 105,900 130,430 126,525
1 101,900 85,440 115,360 78,340
0.3 60,600 59,240 66,650 63,360
0.1 24,220 20,200 29,200 25,650
Mitomycin-treated spleen cells were exposed to culture medium
only, guinea pig complement (C), anti-mouse brain serum plus com-
plement (an anti-T cell reagent), or anti-mouse Ig plus complement.
The stimulating cell dose is the number of cells present in the "no
treatment" population. The actual numbers of cells in the C, anti-
brain + C, and anti-Ig + C populations were 100%, 70%, and 50% of
the number present in the no treatment group. MLRs were run for
4 days in vitro and background [3H]thymidine uptake was 4675 cpm.
This experiment has been performed four times with similar findings.
were strikingly similar (Table 3), indicating that many B or T
cells can be removed without significantly decreasing the MLR
stimulatory capacity of spleen.
Finally, we examined other lymphoid populations as stim-
ulators (Table 4). Spleen and node both stimulated MLRs, with
spleen being more effective than node. Both of these organs
exhibit readily identifiable DCs (1). Thymus and bone marrow,
which lack detectable DCs, stimulated poorly if at all. Purified
allogeneic DCs (105) mixed with 1-3 X 106 allogenic spleen,
node, thymus, or bone marrow cells usually stimulated identi-
cally to purified DCs not mixed with other stimulators (data not
shown), so we conclude that the latter populations do not con-
tain inhibitors of the DC-induced MLR.
We conclude that the main ability of mouse lymphoid organs
to stimulate an MLR does not reside in the major cell sub-
classes-i.e., B and T lymphocytes, and macrophages-but is
due to the presence of small numbers of potent DCs.
DISCUSSION
A considerable literature exists on the ability of B and T lym-
phocytes and macrophages to stimulate the 10 MLR in mouse
and in man (e.g., refs. 8-10). The data in this paper indicate that
DCs may be 100 or more times more potent as stimulating cells
than these other primary lymphoid subpopulations. First we
noted that the MLR-stimulating capacity of spleen cell frac-
tions, separated on the basis of simple physical techniques,
correlated closely with content of DCs and not with numbers
Table 4. MLR-stimulating capacity of different lymphoid organs
Response (cpm [3H]thymidine
Stimulating uptake - background/culture)ceullsdoseafter stimulation with cells from
X 10-6 Spleen Node Thymus Bone marrow
3 65,771 46,125 3655 0
1 51,300 11,906 785 4770
0.3 14,450 2,230 1050 3065
0.1 2,860 0 650 470
Various doses of mitomycin-treated B6D2F1 stimulating cells from
four different lymphoid organs were added to a constant number (5
X 106) C57BL/6 responder spleen cells. Proliferative activity was
measured 4 days later, after a 2-hr pulse of [3H]thymidine at 1.8
,uCi/ml. Background uptake in nonstimulated cultures was 4550 cpm.



































5136 Immunology: Steinman and Witmer
of B and T lymphocytes or macrophages (Fig. 3 and Table 2).
Killing most T or B cells in spleen altered stimulating capacity
little if at all (Table 3). And data from lymphoid organs other
than spleen-e.g., peritoneal cavity, marrow, thymus-sug-
gested again that small numbers of DCs must be present for
MLR stimulation to occur, and/or that DCs are far more
powerful stimulators than these other cells (Tables 1 and 4). An
assumption in our work is that the dose-response data obtained
on purified DCs can be extrapolated to the behavior of DCs in
heterogeneous stimulating mixtures. In most instances, we have
not examined the stimulating capacity of purified lymphoid
subpopulations directly, but data with such populations must
take into account the possibility that trace "contamination" with
DCs could occur.
The contribution made by small numbers of DCs to the MLR
induced by heterogenous cell mixtures must be studied further.
The response itself must be characterized in cultures stimulated
with purified DCs vs. whole spleen. Comparative information
on the Ly phenotype of the responding cells, and the immu-
nologic specificity of the 10 and 20 MLR will be important to
acquire. We do know that the potency of purified DCs in in-
ducing cytotoxic lymphocytes is 100 or more times greater than
that of unfractionated spleen stimulators (M. Nussenzweig,
personal communication). Another area in which more infor-
mation is required is the criteria used to identify and enumerate
DCs. These cells always occur in low frequency; they are pri-
marily identified by a composite of morphologic features seen
by phase contrast microscopy after spreading on glass; and we
have no way of selectively and totally depleting DCs from a
given population. These difficulties might be remedied by the
availability of a specific anti-DC serum.
The mechanism whereby DCs act as such potent 10 MLR
stimulators can only be considered in general terms. The
amount, kind, and distribution of stimulating antigens may
differ on DCs relative to other cell types. Current evidence is
that the I subregion of the mouse major histocompatibility
complex (MHC) encodes the antigenic determinants responsible
for stimulating most of the proliferative activity in an MLR and
that these determinants may correspond to the Ia alloantigens
(11-14). We know that the cytotoxic and indirect immu-
nofluorescence titers of anti-Ia, as well as anti-H-2, sera are
similar towards DCs and other reactive spleen cells. Because
the latter are relatively weak stimulators, we suspect that the
expression of MHC-linked antigens is not solely responsible for
MLR stimulation. Other possibilities exist. The responding
lymphocyte may have to recognize something that exists in or
on DCs in addition to theMHC antigens. Or DCs may influence
the behavior of lymphocytes after the initial recognition event.
After all, the MLR proliferative response we measure after 3-4
days of culture is a complex one in which cells must blast
transform and continue to proliferate rather than die or enter
a nondividing state.
The potency of DCs in inducing a 1° MLR has two additional
implications. The first is whether DCs are present in other or-
gans responsible for stimulating an MLR or even transplantation
reaction in situ. It is possible that DCs and/or their equivalent
are present in peripheral blood and in nonlymphoid organs,
either as intrinsic cells or as "passenger leukocytes" (15). Be-
cause DCs are bone marrow derived (3), there must be a cir-
culating phase whereby they gain access to lymphoid organs,
and possibly to other organs and inflammatory sites. The
lymphoid organs, such as spleen, that we study may be unusual
only in the relative ease with which functioning DCs can be
released and identified.
A second ramification of this paper is that DCs must be
considered in experiments trying to unravel the normal or
physiologic function of the MHC. Considerable evidence has
accumulated that the MHC functions in cell-cell interactions
during many physiologic immune responses (e.g., refs. 16-18).
In some systems, accessory non-T non-B cells seem to express
this function of the MHC (16, 19-21), and most immunologists
feel that the macrophage is the critical accessory cell. The ev-
idence is neither direct nor clear. For example, relatively large
numbers of macrophage-rich populations are required to
achieve optimal effects (16), or peritoneal cells rich in macro-
phages do not function effectively (19, 20), or, in some accessory
cell experiments, histocompatible macrophages are not required
(22). DCs have been distinguished from macrophages in many
significant parameters (23, *), including,in this paper, the ability
to stimulate an MLR. It is possible that DCs have been present
in accessory cell populations mediating MHC-linked effects.
A critical point of this paper is that such small numbers of DCs
are required for responses in alloreactive lymphocytes. We
suggest that DCs and not macrophages will prove to be a critical
accessory cell required in the generation of many immune re-
sponses.
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